The discovery and development of gefapixant
- PMID:34403981
- DOI: 10.1016/j.autneu.2021.102859
The discovery and development of gefapixant
Abstract
Gefapixant is the approved generic name for a compound also known as MK-7264, and prior to that AF-219 and RO-4926219. It is the first-in-class clinically developed antagonist for the P2X3 subtype of trimeric ionotropic purinergic receptors, a family of ATP-gated excitatory ion channels, showing nanomolar potency for the human P2X3 homotrimeric channel and essentially no activity at related channels devoid of P2X3 subunits. As the first P2X3 antagonist to have progressed into clinical studies it has now progressed to the point of successful completion of Phase 3 investigations for the treatment of cough, and the NDA application is under review with US FDA for treatment of refractory chronic cough or unexplained chronic cough. The molecule was discovered in the laboratories of Roche Pharmaceuticals in Palo Alto, California, but clinical development then continued with the formation of Afferent Pharmaceuticals for the purpose of identifying the optimal therapeutic indication for this novel mechanism and establishing a clinical plan for development in the optimal patient populations selected. Geoff Burnstock was a close collaborator and advisor to the P2X3 program for close to two decades of discovery and development. Progression of gefapixant through later stage clinical studies has been conducted by the research laboratories of Merck & Co., Inc., Kenilworth, NJ, USA (MRL; following acquisition of Afferent in 2016), who may commercialize the product once authorization has been granted by regulatory authorities.
Keywords: ATP; Adenosine triphosphate; Cough; Gefapixant; P2X3 receptors; Pain; Purinergic signaling; Respiratory symptoms; Taste.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
- Gefapixant: First Approval.Markham A.Markham A.Drugs. 2022 Apr;82(6):691-695. doi: 10.1007/s40265-022-01700-8.Drugs. 2022.PMID:35347635Review.
- Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators.Smith JA, et al.Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25.Lancet Respir Med. 2020.PMID:32109425Clinical Trial.
- BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.Garceau D, Chauret N.Garceau D, et al.Pulm Pharmacol Ther. 2019 Jun;56:56-62. doi: 10.1016/j.pupt.2019.03.007. Epub 2019 Mar 20.Pulm Pharmacol Ther. 2019.PMID:30902655
- Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.Muccino D, Green S.Muccino D, et al.Pulm Pharmacol Ther. 2019 Jun;56:75-78. doi: 10.1016/j.pupt.2019.03.006. Epub 2019 Mar 14.Pulm Pharmacol Ther. 2019.PMID:30880151Review.
- Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.Nussbaum JC, Hussain A, Min KC, Marbury TC, Lasseter K, Stoch SA, Iwamoto M.Nussbaum JC, et al.J Clin Pharmacol. 2022 Nov;62(11):1435-1444. doi: 10.1002/jcph.2094. Epub 2022 Jul 7.J Clin Pharmacol. 2022.PMID:35656754
Cited by
- Gefapixant: First Approval.Markham A.Markham A.Drugs. 2022 Apr;82(6):691-695. doi: 10.1007/s40265-022-01700-8.Drugs. 2022.PMID:35347635Review.
- ATP, an attractive target for the treatment of refractory chronic cough.Zhang M, Sykes DL, Sadofsky LR, Morice AH.Zhang M, et al.Purinergic Signal. 2022 Sep;18(3):289-305. doi: 10.1007/s11302-022-09877-z. Epub 2022 Jun 21.Purinergic Signal. 2022.PMID:35727480Free PMC article.Review.
- Chronic cough relief by allosteric modulation of P2X3 without taste disturbance.Guo CR, Zhang ZZ, Zhou X, Sun MY, Li TT, Lei YT, Gao YH, Li QQ, Yue CX, Gao Y, Lin YY, Hao CY, Li CZ, Cao P, Zhu MX, Rong MQ, Wang WH, Yu Y.Guo CR, et al.Nat Commun. 2023 Sep 20;14(1):5844. doi: 10.1038/s41467-023-41495-0.Nat Commun. 2023.PMID:37730705Free PMC article.
- Gefapixant, a Novel P2X3 Antagonist, Protects against Post Myocardial Infarction Cardiac Dysfunction and Remodeling Via Suppressing NLRP3 Inflammasome.Wei YZ, Yang S, Li W, Tang YH.Wei YZ, et al.Curr Med Sci. 2023 Feb;43(1):58-68. doi: 10.1007/s11596-022-2658-5. Epub 2023 Jan 9.Curr Med Sci. 2023.PMID:36622629
- Neural control of the lower airways: Role in cough and airway inflammatory disease.Taylor-Clark TE, Undem BJ.Taylor-Clark TE, et al.Handb Clin Neurol. 2022;188:373-391. doi: 10.1016/B978-0-323-91534-2.00013-8.Handb Clin Neurol. 2022.PMID:35965034Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Research Materials